The NFL needs this. Dr Gary Small's study on tracking CTE, the central brain disease in former NFL players, has confirmed its theory in a study published today: it can use PET scans to track the onset of CTE, and it may save the lives of current and former players.
Chronic traumatic encephalopathy (CTE) is caused by the buildup of tau proteins. Small's study, a pilot program, which Deadspin took a close look at last year, uses a specific PET marker that attaches itself to tau proteins and amyloid plaques — the two elements necessary to diagnose Alzheimer's. Tau buildup is known to form after repeated blows to the head, even non-concussions, which happen on nearly every play in the NFL. So tracking tau buildup would allow us to see how much damage a player's brain has undergone.
To this point, there had been no way to track tau before examining the brain at autopsy. The closest ideas used methods traditionally used on Parkinson's or early onset dementia patients, tracking their cognitive decline. The relatively small sample size of Small's study — 45 former players — means further testing will be required, but the results are informative: The scans of the former players' heads were in line with the images of a typical CTE-diagnosed brain at autopsy. While this method isn't perfect — it also tracks and cannot differentiate the unrelated amyloid plaques — it is a massive step forward in diagnosing and addressing CTE.
CTE itself is a degenerative neurological disease. It causes the onset of dementia, and has been found to affect nearly every former NFL player autopsied after its discovery. After years of straight denials, the NFL has finally acknowledged and begun to address the issue. Its efforts to this point have largely been rules-based, and dubiously effective. Improvement will have to come through science.
In June, Dr Julian Bailes, co-founder of the Brain Injury Research Institute who assisted Small, said of the study, "We've autopsied more players than anyone-more than 30 now-and while the science is intriguing, we can only make the diagnosis after death. [Small's study] gives us hope we'll be able to diagnose and identify risk in living patients." Publishing positive results is one more step in that direction. [NYT]
Picture: Jim Cooke for Deadspin